Literature DB >> 21589159

6,8-Dibromo-quinoline.

Ismail Celik, Mehmet Akkurt, Osman Cakmak, Salih Okten, Santiago García-Granda.   

Abstract

The title mol-ecule, C(9)H(5)Br(2)N, is almost planar, with an r.m.s. deviation of 0.027 Å. The dihedral angle between the aromatic rings is 1.5 (3)°. In the crystal, π-π stacking inter-actions are present between the pyridine and benzene rings of adjacent mol-ecules [centroid-centroid distances = 3.634 (4) Å], and short Br⋯Br contacts [3.4443 (13) Å] occur.

Entities:  

Year:  2010        PMID: 21589159      PMCID: PMC3008997          DOI: 10.1107/S1600536810043242

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For the biological and pharmacological activities of quinolines and their derivatives, see: Abadi et al. (2005 ▶); Blackie et al. (2007 ▶); Chen et al. (2006 ▶); Gómez et al. (2008 ▶); Gómez-Barrio et al. (2006 ▶); Kouznetsov et al. (2005 ▶, 2007 ▶); Lindley (1984 ▶); Metwally et al. (2006 ▶); Muscia et al. (2006 ▶); Musiol et al. (2007 ▶); Sissi & Palumbo (2003 ▶); Vangapandu et al. (2004 ▶); Vinsova et al. (2008 ▶); Vladímir et al. (2005 ▶); Zhao et al. (2005 ▶); Zhu et al. (2007 ▶); Şahin et al. (2008 ▶). For the synthesis, see: Ökten et al. (2010 ▶).

Experimental

Crystal data

C9H5Br2N M = 286.94 Monoclinic, a = 7.3436 (12) Å b = 9.8961 (15) Å c = 13.0108 (18) Å β = 109.589 (17)° V = 890.8 (3) Å3 Z = 4 Cu Kα radiation μ = 11.04 mm−1 T = 297 K 0.12 × 0.09 × 0.02 mm

Data collection

Oxford Diffraction Xcalibur diffractometer with a Ruby Gemini CCD detector Absorption correction: part of the refinement model (ΔF) (XABS2; Parkin et al., 1995 ▶)T min = 0.052, T max = 0.080 1598 measured reflections 1598 independent reflections 1075 reflections with I > 2σ(I)

Refinement

R[F 2 > 2σ(F 2)] = 0.045 wR(F 2) = 0.141 S = 1.02 1598 reflections 109 parameters H-atom parameters constrained Δρmax = 0.68 e Å−3 Δρmin = −0.56 e Å−3 Data collection: CrysAlis PRO (Oxford Diffraction, 2009 ▶); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: SIR97 (Altomare et al., 1999 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: ORTEP-3 for Windows (Farrugia, 1999 ▶); software used to prepare material for publication: WinGX (Farrugia, 1997 ▶) and PLATON (Spek, 2009 ▶). Crystal structure: contains datablocks global, I. DOI: 10.1107/S1600536810043242/hb5698sup1.cif Structure factors: contains datablocks I. DOI: 10.1107/S1600536810043242/hb5698Isup2.hkl Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C9H5Br2NF(000) = 544
Mr = 286.94Dx = 2.140 Mg m3
Monoclinic, P21/cCu Kα radiation, λ = 1.54184 Å
Hall symbol: -P 2ybcCell parameters from 1247 reflections
a = 7.3436 (12) Åθ = 3.6–70.3°
b = 9.8961 (15) ŵ = 11.04 mm1
c = 13.0108 (18) ÅT = 297 K
β = 109.589 (17)°Plate, colourless
V = 890.8 (3) Å30.12 × 0.09 × 0.02 mm
Z = 4
Oxford Diffraction Xcalibur diffractometer with a Ruby Gemini CCD detector1598 independent reflections
Radiation source: Enhance (Cu) X-ray Source1075 reflections with I > 2σ(I)
graphiteRint = 0.0000
ω scansθmax = 70.5°, θmin = 5.8°
Absorption correction: part of the refinement model (ΔF) [XABS2 (Parkin et al., 1995); cubic fit to sin(θ)/λ - 24 parameters]h = −8→8
Tmin = 0.052, Tmax = 0.080k = 0→11
1598 measured reflectionsl = 0→15
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.045Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.141H-atom parameters constrained
S = 1.02w = 1/[σ2(Fo2) + (0.0642P)2] where P = (Fo2 + 2Fc2)/3
1598 reflections(Δ/σ)max < 0.001
109 parametersΔρmax = 0.68 e Å3
0 restraintsΔρmin = −0.56 e Å3
Geometry. Bond distances, angles etc. have been calculated using the rounded fractional coordinates. All su's are estimated from the variances of the (full) variance-covariance matrix. The cell e.s.d.'s are taken into account in the estimation of distances, angles and torsion angles
Refinement. Refinement on F2 for ALL reflections except those flagged by the user for potential systematic errors. Weighted R-factors wR and all goodnesses of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The observed criterion of F2 > σ(F2) is used only for calculating -R-factor-obs etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
xyzUiso*/Ueq
Br10.93324 (12)0.16374 (8)0.01474 (6)0.0736 (3)
Br20.54665 (13)0.49672 (10)−0.34185 (6)0.0832 (4)
N10.8781 (8)0.4050 (6)0.1454 (4)0.0641 (19)
C10.8034 (8)0.4311 (7)0.0368 (5)0.055 (2)
C20.8120 (8)0.3287 (6)−0.0384 (5)0.0528 (19)
C30.7418 (9)0.3499 (7)−0.1488 (5)0.0595 (19)
C40.6545 (9)0.4739 (7)−0.1875 (5)0.0550 (19)
C50.6420 (9)0.5744 (7)−0.1208 (5)0.059 (2)
C60.7184 (9)0.5558 (7)−0.0071 (5)0.058 (2)
C70.7125 (10)0.6584 (8)0.0673 (6)0.067 (3)
C80.7919 (11)0.6338 (9)0.1768 (6)0.075 (3)
C90.8687 (11)0.5055 (9)0.2115 (6)0.075 (3)
H30.752100.28330−0.197000.0710*
H50.583300.65570−0.149500.0710*
H70.655600.741400.042200.0800*
H80.794700.701000.227300.0900*
H90.916800.489400.286200.0900*
U11U22U33U12U13U23
Br10.0902 (6)0.0440 (5)0.0739 (5)0.0092 (4)0.0106 (4)0.0044 (3)
Br20.1024 (7)0.0722 (7)0.0649 (5)0.0056 (5)0.0146 (4)0.0115 (4)
N10.065 (3)0.056 (4)0.068 (3)−0.007 (3)0.018 (2)−0.005 (3)
C10.047 (3)0.040 (4)0.074 (4)−0.003 (3)0.014 (3)−0.004 (3)
C20.052 (3)0.033 (4)0.070 (3)0.001 (3)0.016 (3)0.005 (3)
C30.057 (3)0.049 (4)0.066 (3)−0.001 (3)0.012 (3)−0.001 (3)
C40.056 (3)0.046 (4)0.061 (3)−0.001 (3)0.017 (3)0.009 (3)
C50.055 (3)0.043 (4)0.076 (4)0.004 (3)0.019 (3)0.002 (3)
C60.050 (3)0.047 (4)0.078 (4)0.001 (3)0.024 (3)−0.004 (3)
C70.067 (4)0.052 (5)0.084 (4)0.005 (3)0.030 (3)−0.007 (4)
C80.079 (5)0.068 (6)0.084 (5)−0.004 (4)0.036 (4)−0.013 (4)
C90.077 (5)0.078 (6)0.070 (4)−0.016 (4)0.025 (3)−0.015 (4)
Br1—C21.877 (6)C5—C61.407 (9)
Br2—C41.909 (6)C6—C71.414 (10)
N1—C11.358 (8)C7—C81.368 (10)
N1—C91.332 (10)C8—C91.401 (12)
C1—C21.425 (9)C3—H30.9300
C1—C61.414 (10)C5—H50.9300
C2—C31.370 (9)C7—H70.9300
C3—C41.398 (10)C8—H80.9300
C4—C51.343 (9)C9—H90.9300
Br1···Br1i3.4443 (13)
C1—N1—C9116.1 (6)C5—C6—C7122.2 (6)
N1—C1—C2118.9 (6)C6—C7—C8119.0 (7)
N1—C1—C6123.8 (6)C7—C8—C9118.8 (7)
C2—C1—C6117.3 (6)N1—C9—C8124.8 (7)
Br1—C2—C1119.4 (5)C2—C3—H3121.00
Br1—C2—C3119.0 (5)C4—C3—H3121.00
C1—C2—C3121.6 (6)C4—C5—H5120.00
C2—C3—C4118.6 (6)C6—C5—H5120.00
Br2—C4—C3117.5 (5)C6—C7—H7120.00
Br2—C4—C5119.9 (5)C8—C7—H7120.00
C3—C4—C5122.7 (6)C7—C8—H8121.00
C4—C5—C6119.5 (6)C9—C8—H8121.00
C1—C6—C5120.3 (6)N1—C9—H9118.00
C1—C6—C7117.5 (6)C8—C9—H9118.00
C9—N1—C1—C2178.9 (6)C1—C2—C3—C4−2.1 (10)
C9—N1—C1—C6−0.3 (10)C2—C3—C4—C52.1 (11)
C1—N1—C9—C8−1.3 (12)C2—C3—C4—Br2−176.9 (5)
N1—C1—C2—Br1−2.1 (8)Br2—C4—C5—C6178.7 (5)
N1—C1—C2—C3−179.0 (6)C3—C4—C5—C6−0.3 (11)
C6—C1—C2—C30.3 (9)C4—C5—C6—C7179.0 (7)
N1—C1—C6—C5−179.2 (6)C4—C5—C6—C1−1.6 (10)
C6—C1—C2—Br1177.2 (5)C1—C6—C7—C81.4 (11)
C2—C1—C6—C51.6 (10)C5—C6—C7—C8−179.2 (7)
C2—C1—C6—C7−179.0 (6)C6—C7—C8—C9−2.8 (12)
N1—C1—C6—C70.2 (10)C7—C8—C9—N12.9 (13)
Br1—C2—C3—C4−179.0 (5)
  12 in total

1.  Ring-substituted quinolines as potential anti-tuberculosis agents.

Authors:  Suryanarayana Vangapandu; Meenakshi Jain; Rahul Jain; Sukhraj Kaur; Prati Pal Singh
Journal:  Bioorg Med Chem       Date:  2004-05-15       Impact factor: 3.641

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

3.  Synthesis of novel 4-substituted-7-trifluoromethylquinoline derivatives with nitric oxide releasing properties and their evaluation as analgesic and anti-inflammatory agents.

Authors:  Ashraf H Abadi; Gehan H Hegazy; Asmaa A El-Zaher
Journal:  Bioorg Med Chem       Date:  2005-10-15       Impact factor: 3.641

4.  Investigating biological activity spectrum for novel quinoline analogues.

Authors:  Robert Musiol; Josef Jampilek; Katarina Kralova; Des R Richardson; Danuta Kalinowski; Barbara Podeszwa; Jacek Finster; Halina Niedbala; Anna Palka; Jaroslaw Polanski
Journal:  Bioorg Med Chem       Date:  2006-11-14       Impact factor: 3.641

5.  Synthesis and cytotoxic evaluation of certain 4-anilino-2-phenylquinoline derivatives.

Authors:  Yue-Ling Zhao; Yeh-Long Chen; Feng-Shuo Chang; Cherng-Chyi Tzeng
Journal:  Eur J Med Chem       Date:  2005-04-20       Impact factor: 6.514

6.  Synthesis and evaluation of isosteres of N-methyl indolo[3,2-b]-quinoline (cryptolepine) as new antiinfective agents.

Authors:  Xue Y Zhu; Leroy G Mardenborough; Shouming Li; Abdul Khan; Wang Zhang; Pincheng Fan; Melissa Jacob; Shabana Khan; Larry Walker; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2006-11-01       Impact factor: 3.641

7.  Metallocene-based antimalarials: an exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum.

Authors:  Margaret A L Blackie; Paul Beagley; Simon L Croft; Howard Kendrick; John R Moss; Kelly Chibale
Journal:  Bioorg Med Chem       Date:  2007-08-01       Impact factor: 3.641

8.  Synthesis, cytotoxicity, and anti-inflammatory evaluation of 2-(furan-2-yl)-4-(phenoxy)quinoline derivatives. Part 4.

Authors:  Yeh-Long Chen; Yue-Ling Zhao; Chih-Ming Lu; Cherng-Chyi Tzeng; Jih-Pyang Wang
Journal:  Bioorg Med Chem       Date:  2006-03-09       Impact factor: 3.641

Review 9.  The quinolone family: from antibacterial to anticancer agents.

Authors:  Claudia Sissi; Manlio Palumbo
Journal:  Curr Med Chem Anticancer Agents       Date:  2003-11

10.  Structure validation in chemical crystallography.

Authors:  Anthony L Spek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20
View more
  1 in total

1.  3,6,8-Tribromo-quinoline.

Authors:  Ismail Celik; Mehmet Akkurt; Salih Okten; Osman Cakmak; Santiago García-Granda
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-11-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.